UA78741C2 - Fast releasing tablet formulation containing ultrapure fludara and its use - Google Patents

Fast releasing tablet formulation containing ultrapure fludara and its use Download PDF

Info

Publication number
UA78741C2
UA78741C2 UA20040705884A UA20040705884A UA78741C2 UA 78741 C2 UA78741 C2 UA 78741C2 UA 20040705884 A UA20040705884 A UA 20040705884A UA 20040705884 A UA20040705884 A UA 20040705884A UA 78741 C2 UA78741 C2 UA 78741C2
Authority
UA
Ukraine
Prior art keywords
amount
active substance
purity
tablet composition
degree
Prior art date
Application number
UA20040705884A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7711168&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA78741(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of UA78741C2 publication Critical patent/UA78741C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
UA20040705884A 2001-12-20 2002-11-25 Fast releasing tablet formulation containing ultrapure fludara and its use UA78741C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10164510A DE10164510A1 (de) 2001-12-20 2001-12-20 Orale Fludara reinst Formulierung mit schneller Freisetzung des Wirkstoffes
PCT/EP2002/013252 WO2003053418A1 (de) 2001-12-20 2002-11-25 Orale fludara reinst formulierung mit schneller freisetzung des wirkstoffes

Publications (1)

Publication Number Publication Date
UA78741C2 true UA78741C2 (en) 2007-04-25

Family

ID=7711168

Family Applications (1)

Application Number Title Priority Date Filing Date
UA20040705884A UA78741C2 (en) 2001-12-20 2002-11-25 Fast releasing tablet formulation containing ultrapure fludara and its use

Country Status (29)

Country Link
US (1) US7148207B2 (sr)
EP (1) EP1455760B1 (sr)
JP (2) JP2005519043A (sr)
KR (1) KR100884685B1 (sr)
CN (1) CN1306929C (sr)
AR (1) AR037965A1 (sr)
AT (1) ATE303797T1 (sr)
AU (1) AU2002349043B2 (sr)
BR (1) BR0215265A (sr)
CA (1) CA2471396A1 (sr)
DE (2) DE10164510A1 (sr)
DK (1) DK1455760T3 (sr)
EC (1) ECSP045185A (sr)
ES (1) ES2248624T3 (sr)
HR (1) HRP20040648B1 (sr)
IL (2) IL162555A0 (sr)
JO (1) JO2363B1 (sr)
MX (1) MXPA04006005A (sr)
NO (1) NO20043063L (sr)
NZ (1) NZ533701A (sr)
PE (1) PE20030639A1 (sr)
RS (1) RS50398B (sr)
RU (1) RU2318496C2 (sr)
SA (1) SA03240091B1 (sr)
TW (1) TWI255187B (sr)
UA (1) UA78741C2 (sr)
UY (1) UY27596A1 (sr)
WO (1) WO2003053418A1 (sr)
ZA (1) ZA200405735B (sr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2432457A1 (en) * 2009-05-19 2012-03-28 Grindeks, A Joint Stock Company Stable pharmaceutical composition of fludarabine phosphate
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
EP2428201A1 (en) 2010-09-08 2012-03-14 Merck Serono S.A. Oral administration of nucleoside monophosphates
CN101947208B (zh) * 2010-10-09 2012-05-23 江苏奥赛康药业股份有限公司 一种供注射用的磷酸氟达拉滨组合物及其制备方法
CN102091046B (zh) * 2011-02-12 2012-07-18 海南锦瑞制药股份有限公司 一种磷酸氟达拉滨冻干粉针剂及其制备方法
WO2017036356A1 (zh) * 2015-08-28 2017-03-09 浙江海正药业股份有限公司 磷酸氟达拉滨的晶型及其制备方法和用途
CN111423458A (zh) * 2020-04-29 2020-07-17 东南大学 磷酸氟达拉滨杂质h对照品的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903297A (en) * 1973-11-01 1975-09-02 Upjohn Co Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs
US4188378A (en) * 1978-01-04 1980-02-12 The United States Of America As Represented By The Department Of Health, Education And Welfare Anticancer and antiviral activity of 9-β-D-arabinofuranosyl-2-fluoroadenine
US4210745A (en) * 1978-01-04 1980-07-01 The United States Of America As Represented By The Department Of Health, Education And Welfare Procedure for the preparation of 9-β-D-arabinofuranosyl-2-fluoroadenine
US4357324A (en) * 1981-02-24 1982-11-02 The United States Of America As Represented By The Department Of Health And Human Services Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine
DE3323621A1 (de) * 1982-07-08 1984-03-01 Yamasa Shoyu K.K., Choshi, Chiba Pharmazeutisches praeparat mit die antitumor-wirkung verstaerkender wirkung, ein solches praeparat enthaltende chemotherapeutische zusammensetzung und verwendung des praeparates zur unterstuetzung der antitumor-behandlung beim menschen und tier
US5110919A (en) * 1989-12-04 1992-05-05 Ash Stevens, Inc. Process for the preparation of 2-amino-9-(2,3,5-tri-o-benzyl-beta-d-arabinofuranosyl) adenine and novel intermediates
FR2701027B1 (fr) * 1993-02-01 1997-07-18 Warner Lambert Co Procede de synthese ameliore du 9-(beta-d-arabinofuranosyl)adenine 5'-phosphate.
DE19543052A1 (de) 1995-11-06 1997-05-07 Schering Ag Verfahren zur Herstellung und Reinigung von Fludarabin-Phosphat und die Verwendung von sauren Ionenaustauschern im Verfahren
ATE220543T1 (de) * 1996-04-23 2002-08-15 Janssen Pharmaceutica Nv Rasch-freisetzende ph-unabhängige feste dosisformen enthaltend cisaprid
CA2210600A1 (en) * 1996-07-17 1998-01-17 Takashi Houkan Inhibitor of tumor metastasis or recurrence
US6197785B1 (en) * 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
DK1047704T4 (da) * 1997-12-11 2008-03-25 Bayer Schering Pharma Ag Fremgangsmåde til fremstilling af lithium-, kalium-, calcium- og magnesiumsalte af fludarabin-phosphat og rensningsfremgangsmåde til fremstilling af fludarabin-phosphat og fludarabin-phosphat med en renhed på mindst 99,5%
DE69934582T2 (de) 1998-06-11 2007-10-04 Pharmacia & Upjohn Co. Llc, Kalamazoo Delavirdin tablettenformulierung
US6174873B1 (en) * 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
AU6646700A (en) 1999-08-20 2001-03-19 Scripps Research Institute, The Formation of heterocycles
DE60019741T2 (de) 1999-12-08 2006-03-02 Pharmacia Corp., Chicago Nanopartikelzusammensetzungen enthaltend eplerenon
US20020131988A1 (en) 1999-12-16 2002-09-19 Foster Todd P. Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
MXPA02005912A (es) * 1999-12-16 2002-10-23 Upjohn Co Composicion para implante que contiene acetato de melengestrol y acetato de trenbolona.
US6399591B1 (en) * 2000-01-19 2002-06-04 Yung-Shin Pharmaceutical Ind. Co., Ltd. Chargeable pharmaceutical tablets

Also Published As

Publication number Publication date
DE50204203D1 (de) 2005-10-13
HK1077741A1 (en) 2006-02-24
HRP20040648A2 (en) 2004-10-31
US7148207B2 (en) 2006-12-12
CA2471396A1 (en) 2003-07-03
HRP20040648B1 (en) 2012-11-30
ATE303797T1 (de) 2005-09-15
RS50398B (sr) 2009-12-31
KR100884685B1 (ko) 2009-02-18
JP2005519043A (ja) 2005-06-30
CN1617713A (zh) 2005-05-18
US20030176391A1 (en) 2003-09-18
UY27596A1 (es) 2003-07-31
NZ533701A (en) 2006-03-31
KR20040073501A (ko) 2004-08-19
RS53304A (sr) 2006-10-27
TW200305428A (en) 2003-11-01
AU2002349043A1 (en) 2003-07-09
BR0215265A (pt) 2004-12-07
TWI255187B (en) 2006-05-21
RU2004122479A (ru) 2005-05-20
CN1306929C (zh) 2007-03-28
AR037965A1 (es) 2004-12-22
NO20043063L (no) 2004-07-19
MXPA04006005A (es) 2004-09-27
PE20030639A1 (es) 2003-08-28
IL162555A0 (en) 2005-11-20
JP2006137771A (ja) 2006-06-01
JO2363B1 (en) 2006-12-12
AU2002349043B2 (en) 2007-08-16
DE10164510A1 (de) 2003-07-10
WO2003053418A1 (de) 2003-07-03
ZA200405735B (en) 2006-01-25
ECSP045185A (es) 2004-08-27
IL162555A (en) 2008-03-20
PL370792A1 (en) 2005-05-30
DK1455760T3 (da) 2006-01-02
ES2248624T3 (es) 2006-03-16
EP1455760A1 (de) 2004-09-15
EP1455760B1 (de) 2005-09-07
RU2318496C2 (ru) 2008-03-10
SA03240091B1 (ar) 2006-11-25

Similar Documents

Publication Publication Date Title
MY136524A (en) New solid pharmaceutical formulations comprising telmisartan and preparation thereof
MXPA04007427A (es) Formulaciones de azitromicina granuladas por via seca.
UA78741C2 (en) Fast releasing tablet formulation containing ultrapure fludara and its use
JP5524624B2 (ja) 水系フィルムコーティング液、および、フィルムコーティング顆粒、ならびに、これを用いた錠剤
JP6133445B2 (ja) 口腔内速崩壊性固形製剤用組成物
CN111212641A (zh) 阿普斯特的药物组合物
MY137846A (en) Processes for the preparation of oral dosage formulations of modafinil
JP2008516004A5 (sr)
JP2020514351A5 (sr)
JP2010534222A (ja) ダルナビルを含んでなる抗ｈｉｖ錠剤製剤
JP2020186221A (ja) パーキンソン病治療薬の安定化方法
JP5563841B2 (ja) 薬物の不快な味をマスキングした経口医薬組成物
JP4122544B2 (ja) 錠剤組成物
JP3919840B2 (ja) 医薬組成物
AP2001002349A0 (en) Polymorphs of a crystalline azabicyclo (2,2,2) octain-3-amine citrate and their pharmaceutical compositions.
JP4572296B2 (ja) ピモベンダン経口投与製剤
MX9704043A (es) Surtido de farmaco de liberacion sostenida empleando una goma de hidrocoloide en polvo obtenible a partir de plantas superiores.
JP6854182B2 (ja) 口腔用組成物
EP1035869A1 (en) Chemically and thermally stable norastemizole formulations
IL26469A (en) Synergistic pharmaceutical composition containing sulphamethopyrazine and pyrimethamine having antimalarial action
HK1139047A1 (en) Film coating composition
GB1015407A (en) Anorexogenic compositions
YU28404A (sh) Brzo topljiva formulacija za oralno doziranje
HK1077741B (en) Oral fludara of high-purity formulation with quick release of active ingredient